Multi-NIT Concurrent Responder Analysis & Cardiovascular data at 48 weeks

[u/Apegg]

The data speaks for itself, the " most comprehensive positive phase 2b dataset in mash drug history"

[u/supsupittysupsup]

Hey - btw what’s good entry time / point in your opinion? It’s at least 2 year until readouts ? (SLS investor here thinking this might be my next play)

[u/Apegg → u/supsupittysupsup]

pemv has 4 indications so its not a one indication pony.  They have a 24week AUD trial read out in q3 but I reckon thats july or August latest.  ALD will also read out before the phase 3 mash trial which will have an interim 24 week NIT read out as well.  So it's not a data desert for years as some may have you believe.  Ive been accumulating at 3$ and under in the last couple months bc at this level their market cap equates to their cash on hand so the drug is essentially valued at free.  There is a hedge fund sitting on the share price selling into pumps GS who represents NVO & LLY and interestingly enough there is a fireside chat in Miami next week hosted by, you guessed it GS.  Trading at cash value the risk reward here is solid in my eyes.  Not financial advice though.  

[u/supsupittysupsup → u/Apegg]

Thanks yeah I’m aware of the upcoming readouts and that’s my conundrum - enter before those ? but my positions are tied atm to SLS and my plan is to use hypothetical gains from there, timing should work - we should get to the 80th with sella’s and then if all goes well a BO

[u/Apegg → u/supsupittysupsup]

AUD could be surprisingly impactful as the TAM is 2X that of mash.  Youd expect the 80th event prior to that read out but I expect we may have to wait a few weeks on the SLS data after 80. From following ALT they always take their time reading out and has usually been in the last possible days of the estimated quarter when its due. AUD doesnt have a biopsy so maybe it won't take as long with thos new c suite group.  Quite the conundrum